JP2010539186A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010539186A5 JP2010539186A5 JP2010525102A JP2010525102A JP2010539186A5 JP 2010539186 A5 JP2010539186 A5 JP 2010539186A5 JP 2010525102 A JP2010525102 A JP 2010525102A JP 2010525102 A JP2010525102 A JP 2010525102A JP 2010539186 A5 JP2010539186 A5 JP 2010539186A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- independently
- alkyl
- alkenyl
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000001424 substituent group Chemical group 0.000 claims 66
- 125000000217 alkyl group Chemical group 0.000 claims 44
- 125000003342 alkenyl group Chemical group 0.000 claims 43
- 125000000304 alkynyl group Chemical group 0.000 claims 41
- -1 hydroxy, methyl Chemical group 0.000 claims 39
- 125000000623 heterocyclic group Chemical group 0.000 claims 35
- 125000001475 halogen functional group Chemical group 0.000 claims 33
- 125000003545 alkoxy group Chemical group 0.000 claims 31
- 125000004452 carbocyclyl group Chemical group 0.000 claims 29
- 150000001875 compounds Chemical class 0.000 claims 29
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 26
- 150000003839 salts Chemical class 0.000 claims 23
- 125000004043 oxo group Chemical group O=* 0.000 claims 22
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 21
- 125000005133 alkynyloxy group Chemical group 0.000 claims 21
- 125000003302 alkenyloxy group Chemical group 0.000 claims 20
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 20
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 19
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 16
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims 15
- 125000004093 cyano group Chemical group *C#N 0.000 claims 15
- 229910052739 hydrogen Inorganic materials 0.000 claims 15
- 239000001257 hydrogen Substances 0.000 claims 15
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims 12
- 125000005092 alkenyloxycarbonyl group Chemical group 0.000 claims 10
- 125000005198 alkynylcarbonyloxy group Chemical group 0.000 claims 10
- 125000005225 alkynyloxycarbonyl group Chemical group 0.000 claims 10
- 125000005139 alkynylsulfonyl group Chemical group 0.000 claims 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 9
- DYMRYCZRMAHYKE-UHFFFAOYSA-N n-diazonitramide Chemical compound [O-][N+](=O)N=[N+]=[N-] DYMRYCZRMAHYKE-UHFFFAOYSA-N 0.000 claims 9
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 9
- 125000005090 alkenylcarbonyl group Chemical group 0.000 claims 8
- 125000005193 alkenylcarbonyloxy group Chemical group 0.000 claims 8
- 125000005137 alkenylsulfonyl group Chemical group 0.000 claims 8
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 8
- 125000005087 alkynylcarbonyl group Chemical group 0.000 claims 6
- 125000005884 carbocyclylalkyl group Chemical group 0.000 claims 6
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims 6
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- KWEDUNSJJZVRKR-UHFFFAOYSA-N carbononitridic azide Chemical compound [N-]=[N+]=NC#N KWEDUNSJJZVRKR-UHFFFAOYSA-N 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 241000711549 Hepacivirus C Species 0.000 claims 3
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 claims 3
- 125000005097 aminocarbonylalkyl group Chemical group 0.000 claims 3
- CREXVNNSNOKDHW-UHFFFAOYSA-N azaniumylideneazanide Chemical group N[N] CREXVNNSNOKDHW-UHFFFAOYSA-N 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 3
- 125000005091 alkenylcarbonylamino group Chemical group 0.000 claims 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 2
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims 2
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims 2
- 125000005197 alkyl carbonyloxy alkyl group Chemical group 0.000 claims 2
- 125000005088 alkynylcarbonylamino group Chemical group 0.000 claims 2
- 125000006598 aminocarbonylamino group Chemical group 0.000 claims 2
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims 2
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 claims 2
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 2
- 125000006517 heterocyclyl carbonyl group Chemical group 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229920002477 rna polymer Polymers 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 1
- 241001504592 Trachurus trachurus Species 0.000 claims 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- YZDBZOOCRDOXFK-UHFFFAOYSA-N cyano-(diazidoamino)carbamic acid Chemical compound C(=O)(O)N(N(N=[N+]=[N-])N=[N+]=[N-])C#N YZDBZOOCRDOXFK-UHFFFAOYSA-N 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 241001493065 dsRNA viruses Species 0.000 claims 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 1
- 125000005280 halo alkyl sulfonyloxy group Chemical group 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- AMWGUROGSNBGMR-UHFFFAOYSA-N n-[4-[2-[3-cyclopropyl-5-(2,4-dioxo-1,3-diazinan-1-yl)-2-methoxyphenyl]ethynyl]phenyl]methanesulfonamide Chemical compound COC1=C(C#CC=2C=CC(NS(C)(=O)=O)=CC=2)C=C(N2C(NC(=O)CC2)=O)C=C1C1CC1 AMWGUROGSNBGMR-UHFFFAOYSA-N 0.000 claims 1
- RLLFSFIWQNEYIL-UHFFFAOYSA-N n-[4-[2-[3-tert-butyl-5-(2,4-dioxo-1,3-diazinan-1-yl)-2-methoxyphenyl]ethynyl]-3-(trifluoromethyl)phenyl]methanesulfonamide Chemical compound C1=C(C(C)(C)C)C(OC)=C(C#CC=2C(=CC(NS(C)(=O)=O)=CC=2)C(F)(F)F)C=C1N1CCC(=O)NC1=O RLLFSFIWQNEYIL-UHFFFAOYSA-N 0.000 claims 1
- JJOQBONMMNFIBP-UHFFFAOYSA-N n-[4-[2-[3-tert-butyl-5-(2,4-dioxo-1,3-diazinan-1-yl)-2-methoxyphenyl]ethynyl]-3-methylphenyl]methanesulfonamide Chemical compound C1=C(C(C)(C)C)C(OC)=C(C#CC=2C(=CC(NS(C)(=O)=O)=CC=2)C)C=C1N1CCC(=O)NC1=O JJOQBONMMNFIBP-UHFFFAOYSA-N 0.000 claims 1
- MQYIPJLZVCEUNC-UHFFFAOYSA-N n-[4-[2-[3-tert-butyl-5-(2,4-dioxo-1,3-diazinan-1-yl)phenyl]ethynyl]-3-chlorophenyl]methanesulfonamide Chemical compound C=1C(C(C)(C)C)=CC(C#CC=2C(=CC(NS(C)(=O)=O)=CC=2)Cl)=CC=1N1CCC(=O)NC1=O MQYIPJLZVCEUNC-UHFFFAOYSA-N 0.000 claims 1
- JXAZRWXUXDUQGZ-UHFFFAOYSA-N n-[4-[2-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl]ethynyl]-3-(trifluoromethyl)phenyl]methanesulfonamide Chemical compound C1=C(C(C)(C)C)C(OC)=C(C#CC=2C(=CC(NS(C)(=O)=O)=CC=2)C(F)(F)F)C=C1N1C=CC(=O)NC1=O JXAZRWXUXDUQGZ-UHFFFAOYSA-N 0.000 claims 1
- CHWMJTMBVMPENO-UHFFFAOYSA-N n-[4-[2-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl]ethynyl]-3-methylphenyl]methanesulfonamide Chemical compound C1=C(C(C)(C)C)C(OC)=C(C#CC=2C(=CC(NS(C)(=O)=O)=CC=2)C)C=C1N1C=CC(=O)NC1=O CHWMJTMBVMPENO-UHFFFAOYSA-N 0.000 claims 1
- ZTRPQRNGMGNOMB-UHFFFAOYSA-N n-[4-[2-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl]ethynyl]phenyl]methanesulfonamide Chemical compound C1=C(C(C)(C)C)C(OC)=C(C#CC=2C=CC(NS(C)(=O)=O)=CC=2)C=C1N1C=CC(=O)NC1=O ZTRPQRNGMGNOMB-UHFFFAOYSA-N 0.000 claims 1
- ZEEDHMLCVRZTLZ-UHFFFAOYSA-N n-[4-[2-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)phenyl]ethynyl]-3-chlorophenyl]methanesulfonamide Chemical compound C=1C(C(C)(C)C)=CC(C#CC=2C(=CC(NS(C)(=O)=O)=CC=2)Cl)=CC=1N1C=CC(=O)NC1=O ZEEDHMLCVRZTLZ-UHFFFAOYSA-N 0.000 claims 1
- FFJDYHJZZBMVIM-UHFFFAOYSA-N n-[6-[2-[3-tert-butyl-5-(2,4-dioxo-1,3-diazinan-1-yl)-2-methoxyphenyl]ethynyl]pyridin-3-yl]methanesulfonamide Chemical compound C1=C(C(C)(C)C)C(OC)=C(C#CC=2N=CC(NS(C)(=O)=O)=CC=2)C=C1N1CCC(=O)NC1=O FFJDYHJZZBMVIM-UHFFFAOYSA-N 0.000 claims 1
- LHIQDTJNTVZGGE-UHFFFAOYSA-N n-[6-[2-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl]ethynyl]pyridin-3-yl]methanesulfonamide Chemical compound C1=C(C(C)(C)C)C(OC)=C(C#CC=2N=CC(NS(C)(=O)=O)=CC=2)C=C1N1C=CC(=O)NC1=O LHIQDTJNTVZGGE-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229960000329 ribavirin Drugs 0.000 claims 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 1
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 1
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 claims 1
- 230000029812 viral genome replication Effects 0.000 claims 1
- 0 *C(C(*)N(c1cc(I*)c(*)c(*)c1)C(N1*)=O)C1=O Chemical compound *C(C(*)N(c1cc(I*)c(*)c(*)c1)C(N1*)=O)C1=O 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97287707P | 2007-09-17 | 2007-09-17 | |
| US60/972,877 | 2007-09-17 | ||
| US9679108P | 2008-09-13 | 2008-09-13 | |
| US61/096,791 | 2008-09-13 | ||
| PCT/US2008/076576 WO2009039127A1 (en) | 2007-09-17 | 2008-09-17 | Uracil or thymine derivative for treating hepatitis c |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012225875A Division JP2013049681A (ja) | 2007-09-17 | 2012-10-11 | Ｃ型肝炎を治療するためのウラシルまたはチミン誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010539186A JP2010539186A (ja) | 2010-12-16 |
| JP2010539186A5 true JP2010539186A5 (cg-RX-API-DMAC7.html) | 2012-11-15 |
| JP5734654B2 JP5734654B2 (ja) | 2015-06-17 |
Family
ID=39948002
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010525102A Expired - Fee Related JP5734654B2 (ja) | 2007-09-17 | 2008-09-17 | Ｃ型肝炎を治療するためのウラシルまたはチミン誘導体 |
| JP2012225875A Pending JP2013049681A (ja) | 2007-09-17 | 2012-10-11 | Ｃ型肝炎を治療するためのウラシルまたはチミン誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012225875A Pending JP2013049681A (ja) | 2007-09-17 | 2012-10-11 | Ｃ型肝炎を治療するためのウラシルまたはチミン誘導体 |
Country Status (30)
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2014147354A (ru) | 2007-09-17 | 2015-07-10 | Эббви Бахамаз Лтд. | Пиримидины, которые могут быть использованы в качестве противоинфекционных средств, и их применения |
| NZ600371A (en) | 2007-09-17 | 2014-07-25 | Abbvie Bahamas Ltd | Uracil or thymine derivative for treating hepatitis c |
| CN101918369B (zh) * | 2007-09-17 | 2016-02-24 | 艾伯维巴哈马有限公司 | 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物 |
| CN102099351A (zh) * | 2007-11-16 | 2011-06-15 | 先灵公司 | 3-杂环取代的吲哚衍生物及其使用方法 |
| WO2010010017A1 (en) | 2008-07-23 | 2010-01-28 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
| CA2736472A1 (en) | 2008-09-26 | 2010-04-01 | F. Hoffmann-La Roche Ag | Pyrine or pyrazine derivatives for treating hcv |
| CA2753825C (en) * | 2009-03-24 | 2017-10-17 | Abbott Laboratories | Process for preparing substituted pyrimidine antiviral compound |
| MX2011010047A (es) * | 2009-03-25 | 2011-10-11 | Abbott Lab | Compuestos antivirales y usos de los mismos. |
| EP2411007A4 (en) * | 2009-03-27 | 2012-12-05 | Uab Research Foundation | MODULATION OF IRES-MEDIATED TRANSLATION |
| EP2421831A1 (en) | 2009-04-25 | 2012-02-29 | F. Hoffmann-La Roche AG | Heterocyclic antiviral compounds |
| TWI428332B (zh) | 2009-06-09 | 2014-03-01 | Hoffmann La Roche | 雜環抗病毒化合物 |
| CA2762675A1 (en) | 2009-06-24 | 2010-12-29 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compound |
| JP2011057661A (ja) * | 2009-08-14 | 2011-03-24 | Bayer Cropscience Ag | 殺虫性カルボキサミド類 |
| CN102498100A (zh) | 2009-09-21 | 2012-06-13 | 弗·哈夫曼-拉罗切有限公司 | 抗病毒杂环化合物 |
| CA2778206A1 (en) * | 2009-11-21 | 2011-05-26 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
| CA2780526A1 (en) | 2009-12-14 | 2011-06-23 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
| US9216952B2 (en) | 2010-03-23 | 2015-12-22 | Abbvie Inc. | Process for preparing antiviral compound |
| MX2012014235A (es) | 2010-07-07 | 2013-01-28 | Hoffmann La Roche | Compuestos hetericiclicos antiviricos. |
| CR20180412A (es) | 2010-07-16 | 2018-11-01 | Abbvie Ireland Unlimited Co | Proceso para preparar compuestos antivirales |
| AU2015201698B2 (en) * | 2010-07-16 | 2017-02-02 | Abbvie Ireland Unlimited Company | Process for preparing antiviral compounds |
| US8975443B2 (en) | 2010-07-16 | 2015-03-10 | Abbvie Inc. | Phosphine ligands for catalytic reactions |
| US9255074B2 (en) | 2010-07-16 | 2016-02-09 | Abbvie Inc. | Process for preparing antiviral compounds |
| EP3461556A1 (en) | 2010-07-16 | 2019-04-03 | AbbVie Ireland Unlimited Company | Phosphine ligands for catalytic reactions |
| RU2436786C1 (ru) * | 2010-07-23 | 2011-12-20 | Александр Васильевич Иващенко | Замещенные индолы, противовирусный активный компонент, способ получения и применения |
| WO2012020725A1 (ja) * | 2010-08-10 | 2012-02-16 | 塩野義製薬株式会社 | Ｎｐｙ ｙ５受容体拮抗作用を有するヘテロ環誘導体 |
| KR101382730B1 (ko) | 2010-08-13 | 2014-04-08 | 에프. 호프만-라 로슈 아게 | 헤테로환형 항바이러스성 화합물 |
| CN102675092B (zh) * | 2011-03-14 | 2014-11-05 | 江苏中丹药物研究有限公司 | 一种制备2-芳基-2,2-二甲基乙酸甲酯的方法 |
| US9248193B2 (en) | 2011-03-18 | 2016-02-02 | Abbvie Inc. | Formulations of phenyl uracil compounds |
| SG10201602384VA (en) * | 2011-03-31 | 2016-05-30 | Konstanze Schäfer | Perfluorinated compounds for the non-viral transfer of nucleic acids |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| JP5734124B2 (ja) * | 2011-07-21 | 2015-06-10 | 株式会社 東邦アーステック | １，３−ジヨードヒダントイン類の製造方法 |
| CN104024241B (zh) | 2011-08-01 | 2016-01-20 | 大日本住友制药株式会社 | 尿嘧啶衍生物和其用于医学目的的用途 |
| AU2015200715A1 (en) * | 2011-10-21 | 2015-03-05 | Abbvie Ireland Unlimited Company | Methods for treating HCV |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| CN104023726A (zh) | 2011-10-21 | 2014-09-03 | 艾伯维公司 | 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333) |
| GB2506086A (en) | 2011-10-21 | 2014-03-19 | Abbvie Inc | Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon |
| EA026559B1 (ru) | 2012-05-15 | 2017-04-28 | Новартис Аг | Соединения и композиции для ингибирования активности abl1, abl2 и bcr-abl1 |
| KR20150008406A (ko) | 2012-05-15 | 2015-01-22 | 노파르티스 아게 | Abl1, abl2 및 bcr-abl1의 활성을 억제하기 위한 벤즈아미드 유도체 |
| CN104379574B (zh) | 2012-05-15 | 2017-03-01 | 诺华股份有限公司 | 用于抑制abl1、abl2和bcr‑abl1的活性的苯甲酰胺衍生物 |
| HRP20180695T1 (hr) | 2012-05-15 | 2018-06-01 | Novartis Ag | Derivati benzamida za inhibiranje aktivnosti od abl1, abl2 i bcr-abl1 |
| CN104379145A (zh) | 2012-06-27 | 2015-02-25 | 艾伯维公司 | Abt-450和利托那韦和例如abt-072和/或abt-333用于在治疗hcv中使用的联合治疗 |
| WO2014031791A1 (en) | 2012-08-21 | 2014-02-27 | Abbvie Inc. | Process for preparing antiviral compounds |
| AU2013330993B2 (en) | 2012-10-18 | 2018-03-01 | Abbvie Inc. | Formulations of pyrimidinedione derivative compounds |
| JP2014101316A (ja) * | 2012-11-20 | 2014-06-05 | Toyobo Co Ltd | ベンゾ［１，２−ｄ；４，５−ｄ’］ビスチアゾール化合物の製造方法 |
| CA2916912A1 (en) | 2013-07-02 | 2015-01-08 | Abbvie Inc. | Methods for treating hcv |
| JP6423873B2 (ja) | 2013-07-08 | 2018-11-14 | バイエル・クロップサイエンス・アクチェンゲゼルシャフト | 有害生物防除剤としての６員ｃ−ｎ−結合アリールスルフィド誘導体及びアリールスルホキシド誘導体 |
| EP3043803B1 (en) | 2013-09-11 | 2022-04-27 | Emory University | Nucleotide and nucleoside compositions and their uses |
| EP3089757A1 (en) | 2014-01-03 | 2016-11-09 | AbbVie Inc. | Solid antiviral dosage forms |
| EP3099295A1 (en) | 2014-01-28 | 2016-12-07 | Abbvie Inc. | Dose adjustment in combination therapy of hepatitis c |
| DK3102576T3 (da) | 2014-02-03 | 2019-07-22 | Vitae Pharmaceuticals Llc | Dihydropyrrolopyridininhibitorer af ror-gamma |
| CN106065009B (zh) * | 2014-06-28 | 2019-03-01 | 广东东阳光药业有限公司 | 作为丙型肝炎抑制剂的化合物及其在药物中的应用 |
| WO2016004513A1 (en) * | 2014-07-11 | 2016-01-14 | Simon Fraser University | Anti-bacterial pyruvate kinase modulator compounds, compositions, uses and methods |
| EP3174868B1 (en) | 2014-08-01 | 2021-08-25 | Nuevolution A/S | Compounds active towards bromodomains |
| WO2016040588A1 (en) | 2014-09-11 | 2016-03-17 | Abbvie Inc. | Treatment of hcv by administering four different anti-hcv compounds with food |
| MX371304B (es) | 2014-10-14 | 2020-01-24 | Vitae Pharmaceuticals Llc | Dihidropirrolopiridinas inhibidoras del receptor huérfano-gamma. |
| US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
| WO2016105547A1 (en) | 2014-12-24 | 2016-06-30 | Concert Pharmaceuticals, Inc. | Deuterated dasabuvir |
| RU2590952C1 (ru) * | 2015-05-26 | 2016-07-10 | Вячеслав Энгельсович Семёнов | Средство гепатопротекторного действия |
| WO2016196280A1 (en) | 2015-06-02 | 2016-12-08 | E I Du Pont De Nemours And Company | Heterocycle-substituted bicyclic pesticides |
| WO2017019828A1 (en) * | 2015-07-30 | 2017-02-02 | Bristol-Myers Squibb Company | Aryl substituted bicyclic heteroaryl compounds |
| WO2017024018A1 (en) | 2015-08-05 | 2017-02-09 | Vitae Pharmaceuticals, Inc. | Modulators of ror-gamma |
| AU2016355710B2 (en) | 2015-11-20 | 2021-03-25 | Vitae Pharmaceuticals, Llc | Modulators of ROR-gamma |
| TW202220968A (zh) | 2016-01-29 | 2022-06-01 | 美商維它藥物有限責任公司 | ＲＯＲ－γ調節劑 |
| US11192914B2 (en) | 2016-04-28 | 2021-12-07 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| US9481674B1 (en) | 2016-06-10 | 2016-11-01 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| UA126583C2 (uk) | 2017-07-24 | 2022-11-02 | Вітае Фармасьютікалс, Ллс | ІНГІБІТОРИ ROR<font face="Symbol">g</font> |
| WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | INHIBITORS OF ROR GAMMA |
| CN107266373A (zh) * | 2017-08-01 | 2017-10-20 | 安徽拜善晟制药有限公司 | 一种原料药达沙布韦的制备方法 |
| US11613543B2 (en) | 2018-03-26 | 2023-03-28 | Novartis Ag | Substituted pyrrolo[2,3-d]pyrimidines as Bruton's Tyrosine Kinase inhibitors |
| CN110483496B (zh) * | 2019-07-17 | 2021-05-04 | 杭州市西溪医院 | 一类具有尿嘧啶-苯并噻唑结构衍生物、其制备方法及抗hcv药物的应用 |
| EP4031247A1 (en) * | 2019-09-16 | 2022-07-27 | Novartis AG | Bifunctional degraders and their methods of use |
| EP3819006A1 (en) | 2019-11-05 | 2021-05-12 | Technische Universität Dresden | Compounds with thymine skeleton for use in medicine |
| CN111518036A (zh) * | 2020-04-29 | 2020-08-11 | 杭州勇诚睿生物科技有限公司 | 一种达沙布韦关键中间体的制备方法 |
| US12274700B1 (en) | 2020-10-30 | 2025-04-15 | Accencio LLC | Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4239888A (en) * | 1974-11-04 | 1980-12-16 | Pfizer Inc. | 1-Phenyluracils |
| JPS60243017A (ja) | 1984-05-16 | 1985-12-03 | Kyowa Hakko Kogyo Co Ltd | 抗けいれん組成物 |
| US5084084A (en) | 1989-07-14 | 1992-01-28 | Nissan Chemical Industries Ltd. | Uracil derivatives and herbicides containing the same as active ingredient |
| AU627906B2 (en) | 1989-07-14 | 1992-09-03 | Nissan Chemical Industries Ltd. | Uracil derivatives and herbicides containing the same as active ingredient |
| CA2036304C (en) | 1990-02-15 | 2001-04-17 | Takehiko Naka | Pyrimidinedione derivatives, their production and use |
| NL9001075A (cg-RX-API-DMAC7.html) | 1990-05-04 | 1991-12-02 | Duphar Int Res | |
| EP0489480A1 (en) * | 1990-12-05 | 1992-06-10 | Nissan Chemical Industries Ltd. | Uracil derivatives and herbicides containing the same as active ingredient |
| JPH05213755A (ja) | 1992-02-07 | 1993-08-24 | Nikko Kyodo Co Ltd | 肝臓障害治療薬 |
| DE19528305A1 (de) | 1995-08-02 | 1997-02-06 | Bayer Ag | Substituierte Phenyluracile |
| CZ303435B6 (cs) | 1999-12-06 | 2012-09-12 | F. Hoffmann-La Roche Ag | 4-Pyrimidinyl-N-acyl-1-fenylalanin, meziprodukt pro jeho prípravu a farmaceutická kompozice |
| US6380387B1 (en) | 1999-12-06 | 2002-04-30 | Hoffmann-La Roche Inc. | 4-Pyrimidinyl-n-acyl-l phenylalanines |
| RU2264395C2 (ru) * | 2000-02-04 | 2005-11-20 | Сумитомо Кемикал Компани, Лимитед | Производные урацила, гербицидная композиция, способ борьбы с сорняками и промежуточные продукты (варианты) |
| IL167955A (en) | 2000-02-04 | 2007-10-31 | Sumitomo Chemical Co | Inilines are converted by troiril |
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| TW200505872A (en) * | 2003-06-13 | 2005-02-16 | Lg Life Science Ltd | Hepatitis C virus inhibitors |
| US7163937B2 (en) | 2003-08-21 | 2007-01-16 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
| AR061570A1 (es) * | 2006-06-23 | 2008-09-03 | Smithkline Beecham Corp | Compuesto de glicina sustituido en el n heteroaromatico composicion farmaceutica que lo comprende, su uso para preparar un medicamento, procedimientos para preparar dicha composicion farmaceutica y para preparar el compuesto |
| RU2014147354A (ru) * | 2007-09-17 | 2015-07-10 | Эббви Бахамаз Лтд. | Пиримидины, которые могут быть использованы в качестве противоинфекционных средств, и их применения |
| CN101918369B (zh) * | 2007-09-17 | 2016-02-24 | 艾伯维巴哈马有限公司 | 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物 |
| NZ600371A (en) | 2007-09-17 | 2014-07-25 | Abbvie Bahamas Ltd | Uracil or thymine derivative for treating hepatitis c |
| WO2010010017A1 (en) | 2008-07-23 | 2010-01-28 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
-
2008
- 2008-09-17 NZ NZ600371A patent/NZ600371A/en unknown
- 2008-09-17 CN CN200880107764.3A patent/CN101801935B/zh not_active Expired - Fee Related
- 2008-09-17 CL CL2008002794A patent/CL2008002794A1/es unknown
- 2008-09-17 BR BRPI0816994A patent/BRPI0816994B8/pt active IP Right Grant
- 2008-09-17 MX MX2010002905A patent/MX2010002905A/es active IP Right Grant
- 2008-09-17 EP EP08831873.8A patent/EP2222646B1/en not_active Not-in-force
- 2008-09-17 JP JP2010525102A patent/JP5734654B2/ja not_active Expired - Fee Related
- 2008-09-17 NZ NZ618277A patent/NZ618277A/en not_active IP Right Cessation
- 2008-09-17 CA CA2976793A patent/CA2976793A1/en not_active Abandoned
- 2008-09-17 EP EP13193524.9A patent/EP2725015A1/en not_active Withdrawn
- 2008-09-17 PE PE2008001621A patent/PE20090705A1/es active IP Right Grant
- 2008-09-17 PE PE2012002073A patent/PE20130209A1/es not_active Application Discontinuation
- 2008-09-17 SG SG2012060521A patent/SG183733A1/en unknown
- 2008-09-17 CN CN201210157072.8A patent/CN102746239B/zh not_active Expired - Fee Related
- 2008-09-17 TW TW103110394A patent/TWI534137B/zh not_active IP Right Cessation
- 2008-09-17 MY MYPI2010001141A patent/MY162760A/en unknown
- 2008-09-17 NZ NZ584720A patent/NZ584720A/en not_active IP Right Cessation
- 2008-09-17 AR ARP080104045A patent/AR070027A1/es active IP Right Grant
- 2008-09-17 KR KR1020157010052A patent/KR101660360B1/ko not_active Expired - Fee Related
- 2008-09-17 PA PA20088796201A patent/PA8796201A1/es unknown
- 2008-09-17 IN IN5113DEN2012 patent/IN2012DN05113A/en unknown
- 2008-09-17 TW TW097135721A patent/TWI437994B/zh active
- 2008-09-17 WO PCT/US2008/076576 patent/WO2009039127A1/en not_active Ceased
- 2008-09-17 UY UY31344A patent/UY31344A1/es active IP Right Grant
- 2008-09-17 KR KR1020107008431A patent/KR101552474B1/ko active Active
- 2008-09-17 UA UAA201302816A patent/UA117800C2/uk unknown
- 2008-09-17 ES ES08831873.8T patent/ES2453591T3/es active Active
- 2008-09-17 RU RU2010114828/04A patent/RU2543620C2/ru not_active IP Right Cessation
- 2008-09-17 AU AU2008302448A patent/AU2008302448B2/en active Active
- 2008-09-17 CA CA2699981A patent/CA2699981C/en not_active Expired - Fee Related
-
2010
- 2010-03-15 GT GT201000061A patent/GT201000061A/es unknown
- 2010-03-16 MX MX2012004779A patent/MX338555B/es unknown
- 2010-03-16 DO DO2010000084A patent/DOP2010000084A/es unknown
- 2010-03-16 CR CR11316A patent/CR11316A/es unknown
- 2010-03-16 IL IL204547A patent/IL204547A/en active Protection Beyond IP Right Term
- 2010-03-16 CO CO10030957A patent/CO6260076A2/es active IP Right Grant
- 2010-03-17 US US12/725,689 patent/US8415351B2/en not_active Expired - Fee Related
- 2010-12-21 DO DO2010000396A patent/DOP2010000396A/es unknown
-
2012
- 2012-04-03 US US13/438,609 patent/US8685991B2/en not_active Expired - Fee Related
- 2012-06-08 ZA ZA2012/04224A patent/ZA201204224B/en unknown
- 2012-06-08 ZA ZA2012/04223A patent/ZA201204223B/en unknown
- 2012-08-06 AR ARP120102873A patent/AR087472A2/es unknown
- 2012-10-11 JP JP2012225875A patent/JP2013049681A/ja active Pending
-
2013
- 2013-02-01 RU RU2013104270/04A patent/RU2599635C2/ru not_active IP Right Cessation
- 2013-02-06 CL CL2013000372A patent/CL2013000372A1/es unknown
- 2013-02-25 PH PH12013500365A patent/PH12013500365A1/en unknown
-
2014
- 2014-03-31 US US14/230,965 patent/US9095590B2/en not_active Expired - Fee Related
-
2015
- 2015-05-08 CR CR20150238A patent/CR20150238A/es unknown